Onureg

Do not substitute for IV or SC azacitidine. Not recommended for treating myelodysplastic syndromes. Myelosuppression. Monitor CBCs every other week for the first 2 cycles and prior to each cycle thereafter; increase monitoring after any dose reduction for myelosuppression. Do not administer if ANC <0.5Gi/L on Day 1 of a cycle; delay initiation until ANC ≥0.5Gi/L. Severe renal impairment (CrCl 15–29mL/min): monitor frequently and adjust dose as needed. Pre-existing severe hepatic impairment (total bilirubin >3×ULN). Embryo-fetal toxicity. Advise to use effective contraception during and for ≥6 months (females of reproductive potential) or ≥3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).